{"id":3923,"date":"2020-11-02T08:01:21","date_gmt":"2020-11-02T07:01:21","guid":{"rendered":"https:\/\/www.ab-science.com\/ab8939-en-oncologie\/"},"modified":"2026-09-29T10:40:00","modified_gmt":"2026-09-29T08:40:00","slug":"ab8939-en-oncologie","status":"publish","type":"page","link":"https:\/\/ab-science.excalibra.com\/fr\/science\/ab8939-en-oncologie\/","title":{"rendered":"AB8939 en oncologie"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text el_class=\u00a0\u00bbab-science-page-intro\u00a0\u00bb]<\/p>\n

AB8939 est un d\u00e9stabilisateur synth\u00e9tique des microtubules, de nouvelle g\u00e9n\u00e9ration.<\/div>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]

<\/span>Facteurs cl\u00e9s de diff\u00e9renciation d'AB8939<\/span><\/div><\/div>
<\/div>[vc_column_text]Le compos\u00e9 AB8939 est un inhibiteur de la tubuline de synth\u00e8se, de structure in\u00e9dite, appartenant \u00e0 la classe des petites mol\u00e9cules chimiques, qui peut contourner la r\u00e9sistance m\u00e9di\u00e9e par la glycoprot\u00e9ine P (Pgp) et la my\u00e9loperoxydase (MPO), conf\u00e9rant ainsi un avantage important sur les inhibiteurs de la tubuline traditionnels.<\/p>\n

AB8939 est d\u00e9velopp\u00e9 en premi\u00e8re indication dans la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb (LMA), car les cellules canc\u00e9reuses y prolif\u00e8rent rapidement. Sur les lign\u00e9es HL-60 et U-937, AB8939 inhibe la prolif\u00e9ration avec une CI50<\/sub> d\u2019environ 5 nM, contre plus de 1 000 nM pour la doxorubicine. Cette insensibilit\u00e9 \u00e0 la my\u00e9loperoxydase constitue un avantage par rapport aux alcalo\u00efdes de la pervenche (vincristine ou vinblastine).<\/p>\n

L’objectif d’AB Science avec le compos\u00e9 AB8939 a \u00e9t\u00e9 de concevoir un m\u00e9dicament ultra-s\u00e9lectif \u00e0 petites mol\u00e9cules, ayant de fortes propri\u00e9t\u00e9s antiprolif\u00e9ratives et un profil de s\u00e9curit\u00e9 acceptable avec une toxicit\u00e9 cardiaque ou neuronale minimale.[\/vc_column_text]

<\/span>Donn\u00e9es pr\u00e9cliniques d'AB8939<\/span><\/div><\/div>
<\/div>[vc_row_inner content_placement=\u00a0\u00bbtop\u00a0\u00bb][vc_column_inner][vc_column_text]Le potentiel th\u00e9rapeutique d’AB8939 dans la LMA a \u00e9t\u00e9 d\u00e9montr\u00e9 \u00e0 l’aide de mod\u00e8les de x\u00e9nogreffes d\u00e9riv\u00e9es de patients (PDX) r\u00e9sistants \u00e0 la cytarabine (Ara-C) et \u00e0 l’azacitidine4<\/sup>. L’Ara-C est consid\u00e9r\u00e9 comme l’agent cytotoxique le plus pertinent sur le plan clinique pour le traitement de la LMA, tandis que l’azacitidine est un agent hypom\u00e9thylant largement utilis\u00e9 pour la LMA1, 2, 3<\/sup>.<\/p>\n

AB8939 a consid\u00e9rablement r\u00e9duit la concentration de blastes dans le sang (38 jours apr\u00e8s la greffe), la moelle osseuse (BM) et la rate (52 jours apr\u00e8s la greffe) par rapport \u00e0 l’azacitidine (Vidaza\u00ae)4<\/sup>.<\/p>\n

Le potentiel th\u00e9rapeutique d’AB8939 dans la LMA a \u00e9t\u00e9 d\u00e9montr\u00e9 in vivo \u00e0 l’aide d’un mod\u00e8le PDX r\u00e9sistant \u00e0 l’Ara-C. En monoth\u00e9rapie, AB8939 a consid\u00e9rablement r\u00e9duit la concentration de blastes dans le sang et la moelle osseuse et a diminu\u00e9 la croissance tumorale par rapport \u00e0 l’Ara-C.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column]

<\/span>D\u00e9veloppement clinique<\/span><\/div><\/div>
<\/div>[vc_column_text]<\/p>\n

AB8939 fait l\u2019objet de l\u2019\u00e9tude de phase 1\/2 AB18001 (NCT05211570)<\/a>, ouverte depuis juin 2022, chez des patients atteints de leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb en rechute ou r\u00e9fractaire. Les trois premi\u00e8res \u00e9tapes de la phase 1 sont achev\u00e9es ; l\u2019\u00e9tape 3, \u00e9valuant l\u2019association d\u2019AB8939 au v\u00e9n\u00e9toclax, a \u00e9t\u00e9 rapport\u00e9e en juin 2026. AB8939 a re\u00e7u la d\u00e9signation de m\u00e9dicament orphelin dans la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb de la Food and Drug Administration le 7 novembre 2019 et de l\u2019Agence europ\u00e9enne des m\u00e9dicaments le 23 avril 2025.<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]R\u00e9f\u00e9rences<\/strong><\/em><\/p>\n

    \n
  1. Humbert M, et al. Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939. Blood. 2019;134(Supplement 1):2075. doi:10.1182\/blood-2019-122540<\/em><\/li>\n
  2. Goubard A, et al. In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-Derived Xenograft Models of Acute Myeloid Leukemia. Blood. 2019;134(Supplement 1):5142. doi:10.1182\/blood-2019-127143<\/em><\/li>\n
  3. Goubard A, et al. AB8939, a Microtubule-Destabilizing Agent with Potential to Overcome Multidrug Resistance, Is Active across the Range (M0-M7) of Acute Myeloid Leukemia Subtypes. Blood. 2019;134(Supplement 1):5154. doi:10.1182\/blood-2019-127021<\/em><\/li>\n
  4. Humbert M, Letard S, Goubard A, et al. Identification of AB8939, a novel synthetic microtubule destabilizer and ALDH inhibitor that overcomes multidrug resistance in tumor cells as a drug candidate for the treatment of refractory acute myeloid leukemia. bioRxiv. 2025. Pr\u00e9publication. doi:10.64898\/2025.12.10.692519<\/a>.<\/em><\/li>\n<\/ol>\n

    [\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

    [vc_row][vc_column][vc_column_text el_class=\u00a0\u00bbab-science-page-intro\u00a0\u00bb] AB8939 est un d\u00e9stabilisateur synth\u00e9tique des microtubules, de nouvelle g\u00e9n\u00e9ration. [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]Le compos\u00e9 AB8939 est un inhibiteur de la tubuline de synth\u00e8se, de structure in\u00e9dite, appartenant \u00e0 la classe des petites mol\u00e9cules chimiques, qui peut contourner la r\u00e9sistance m\u00e9di\u00e9e par la glycoprot\u00e9ine P (Pgp) et la my\u00e9loperoxydase (MPO), conf\u00e9rant ainsi un avantage important sur…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3970,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3923","page","type-page","status-publish","hentry","description-off"],"yoast_head":"\nAB8939 en oncologie – AB Science<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB8939 en oncologie\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text el_class=\u00a0\u00bbab-science-page-intro\u00a0\u00bb] AB8939 est un d\u00e9stabilisateur synth\u00e9tique des microtubules, de nouvelle g\u00e9n\u00e9ration. [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]Le compos\u00e9 AB8939 est un inhibiteur de la tubuline de synth\u00e8se, de structure in\u00e9dite, appartenant \u00e0 la classe des petites mol\u00e9cules chimiques, qui peut contourner la r\u00e9sistance m\u00e9di\u00e9e par la glycoprot\u00e9ine P (Pgp) et la my\u00e9loperoxydase (MPO), conf\u00e9rant ainsi un avantage important sur…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ab-science.excalibra.com\/fr\/science\/ab8939-en-oncologie\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-29T08:40:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/science\\\/ab8939-en-oncologie\\\/\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/science\\\/ab8939-en-oncologie\\\/\",\"name\":\"AB8939 en oncologie – AB Science\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-11-02T07:01:21+00:00\",\"dateModified\":\"2026-09-29T08:40:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/science\\\/ab8939-en-oncologie\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/science\\\/ab8939-en-oncologie\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/science\\\/ab8939-en-oncologie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Science\",\"item\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"AB8939 en oncologie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AB8939 en oncologie – AB Science","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"AB8939 en oncologie","og_description":"[vc_row][vc_column][vc_column_text el_class=\u00a0\u00bbab-science-page-intro\u00a0\u00bb] AB8939 est un d\u00e9stabilisateur synth\u00e9tique des microtubules, de nouvelle g\u00e9n\u00e9ration. [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]Le compos\u00e9 AB8939 est un inhibiteur de la tubuline de synth\u00e8se, de structure in\u00e9dite, appartenant \u00e0 la classe des petites mol\u00e9cules chimiques, qui peut contourner la r\u00e9sistance m\u00e9di\u00e9e par la glycoprot\u00e9ine P (Pgp) et la my\u00e9loperoxydase (MPO), conf\u00e9rant ainsi un avantage important sur…","og_url":"https:\/\/ab-science.excalibra.com\/fr\/science\/ab8939-en-oncologie\/","og_site_name":"AB Science","article_modified_time":"2026-09-29T08:40:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ab-science.excalibra.com\/fr\/science\/ab8939-en-oncologie\/","url":"https:\/\/ab-science.excalibra.com\/fr\/science\/ab8939-en-oncologie\/","name":"AB8939 en oncologie – AB Science","isPartOf":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#website"},"datePublished":"2020-11-02T07:01:21+00:00","dateModified":"2026-09-29T08:40:00+00:00","breadcrumb":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/science\/ab8939-en-oncologie\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ab-science.excalibra.com\/fr\/science\/ab8939-en-oncologie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ab-science.excalibra.com\/fr\/science\/ab8939-en-oncologie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ab-science.excalibra.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Science","item":"https:\/\/ab-science.excalibra.com\/fr\/science\/"},{"@type":"ListItem","position":3,"name":"AB8939 en oncologie"}]},{"@type":"WebSite","@id":"https:\/\/ab-science.excalibra.com\/fr\/#website","url":"https:\/\/ab-science.excalibra.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ab-science.excalibra.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ab-science.excalibra.com\/fr\/#organization","name":"AB Science","url":"https:\/\/ab-science.excalibra.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ab-science.excalibra.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]}]}},"_links":{"self":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/3923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/comments?post=3923"}],"version-history":[{"count":7,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/3923\/revisions"}],"predecessor-version":[{"id":11847,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/3923\/revisions\/11847"}],"up":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/3970"}],"wp:attachment":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/media?parent=3923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}